Edwards Lifesciences Corporation (NYSE:EW) has earned a consensus recommendation of “Buy” from the twenty-three brokerages that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $120.32.

EW has been the topic of several recent research reports. Barclays PLC restated an “equal weight” rating and issued a $120.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Saturday. Zacks Investment Research lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 26th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. BMO Capital Markets reiterated a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Finally, William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded up 0.62% on Wednesday, hitting $109.99. The company had a trading volume of 1,665,942 shares. The stock’s 50-day moving average is $113.80 and its 200 day moving average is $109.37. The company has a market capitalization of $23.23 billion, a price-to-earnings ratio of 33.36 and a beta of 0.62. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. Edwards Lifesciences Corporation’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the business earned $0.76 earnings per share. Equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

In other Edwards Lifesciences Corporation news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $111.81, for a total transaction of $2,119,917.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 176,901 shares of company stock worth $20,191,196. Insiders own 2.13% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. UBS Asset Management Americas Inc. raised its position in shares of Edwards Lifesciences Corporation by 7.8% during the 1st quarter. UBS Asset Management Americas Inc. now owns 574,126 shares of the medical research company’s stock valued at $54,008,000 after buying an additional 41,636 shares during the period. RKL Wealth Management LLC raised its position in Edwards Lifesciences Corporation by 117.3% in the first quarter. RKL Wealth Management LLC now owns 5,905 shares of the medical research company’s stock valued at $555,000 after purchasing an additional 3,187 shares during the period. Marcus Capital LLC raised its position in Edwards Lifesciences Corporation by 29.3% in the first quarter. Marcus Capital LLC now owns 22,850 shares of the medical research company’s stock valued at $2,149,000 after purchasing an additional 5,175 shares during the period. Raymond James Financial Services Advisors Inc. raised its position in Edwards Lifesciences Corporation by 9.3% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 7,821 shares of the medical research company’s stock valued at $736,000 after purchasing an additional 665 shares during the period. Finally, Mason Street Advisors LLC raised its position in Edwards Lifesciences Corporation by 0.4% in the first quarter. Mason Street Advisors LLC now owns 29,365 shares of the medical research company’s stock valued at $2,762,000 after purchasing an additional 116 shares during the period. 82.08% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Edwards Lifesciences Corporation (EW) Receives $120.32 Average Price Target from Analysts” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/02/edwards-lifesciences-corporation-ew-receives-120-32-average-price-target-from-analysts.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.